NVO: Novo Nordisk A/S
About
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Current Value
$103.431 Year Return
Current Value
$103.431 Year Return
Key Details
Market Cap
$342.62B
P/E Ratio
33.21
1Y Stock Return
-0.15%
1Y Revenue Growth
27.73%
Dividend Yield
0.94%
Price to Book
19.0
Strategies that include NVO
Stock's related to NVO
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LLY | 59.91% | $692.74B | +23.14% | 0.71% |
| CDNS | 37.85% | $82.18B | +10.81% | 0.00% |
| SNPS | 35.74% | $82.03B | -1.18% | 0.00% |
| ASML | 35.49% | $260.51B | -3.25% | 1.03% |
| NVMI | 35.34% | $5.16B | +44.02% | 0.00% |
| ONTO | 33.73% | $8.04B | +20.50% | 0.00% |
| ISRG | 33.11% | $191.92B | +72.80% | 0.00% |
| SYK | 32.74% | $148.17B | +32.36% | 0.82% |
| RDNT | 32.26% | $5.91B | +151.89% | 0.00% |
| AMAT | 32.25% | $139.58B | +13.44% | 0.85% |
| LRCX | 32.17% | $90.29B | -0.80% | 11.86% |
| BSX | 32.08% | $133.13B | +63.29% | 0.00% |
| KLAC | 31.51% | $82.35B | +11.80% | 0.98% |
| VECO | 31.48% | $1.48B | -9.94% | 0.00% |
| CAMT | 31.45% | $3.40B | +16.39% | 0.00% |
| BRKR | 31.39% | $7.31B | -25.31% | 0.39% |
| CR | 31.29% | $10.21B | +67.24% | 0.45% |
| PSO | 30.45% | $10.32B | +25.72% | 1.95% |
| IMRN | 30.10% | $10.31M | -5.04% | 0.00% |
| TDG | 29.92% | $70.32B | +35.98% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MRO | <0.01% | $16.08B | +13.59% | 1.53% |
| GLPG | 0.01% | $1.76B | -27.61% | 0.00% |
| HZO | -0.01% | $668.35M | -1.96% | 0.00% |
| TKO | -0.02% | $10.62B | +67.14% | 0.00% |
| BSIG | 0.02% | $1.12B | +69.17% | 0.13% |
| MGEE | -0.02% | $3.78B | +41.56% | 1.66% |
| XGN | 0.03% | $62.26M | +127.74% | 0.00% |
| MTLS | 0.03% | $399.00M | +3.76% | 0.00% |
| TASK | -0.03% | $1.27B | +16.72% | 0.00% |
| GEF | -0.04% | $3.88B | +0.12% | 3.11% |
| WBS | -0.04% | $10.28B | +38.44% | 2.67% |
| KT | -0.05% | $7.55B | +19.08% | 6.85% |
| LNT | 0.05% | $15.97B | +26.81% | 3.08% |
| GIII | 0.08% | $1.28B | +4.84% | 0.00% |
| FCNCA | -0.08% | $31.02B | +54.47% | 0.30% |
| VSTA | -0.08% | $204.94M | -39.33% | 0.00% |
| ALK | -0.08% | $6.74B | +44.79% | 0.00% |
| ANDE | 0.08% | $1.61B | -9.16% | 1.61% |
| PRAA | -0.08% | $880.00M | +25.68% | 0.00% |
| OPTN | -0.09% | $51.10M | -72.23% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CPB | -22.47% | $12.96B | +7.08% | 3.40% |
| RVLV | -22.47% | $2.35B | +127.64% | 0.00% |
| CBOE | -21.89% | $21.46B | +15.84% | 1.11% |
| FDP | -19.34% | $1.62B | +45.67% | 2.97% |
| GIS | -17.08% | $34.85B | -2.91% | 3.78% |
| TPVG | -16.86% | $272.08M | - | 18.82% |
| TPB | -16.35% | $1.08B | +167.44% | 0.45% |
| MEI | -16.14% | $326.37M | -60.53% | 6.06% |
| HAE | -15.45% | $4.26B | +2.89% | 0.00% |
| HUSA | -15.32% | $16.69M | -11.56% | 0.00% |
| SPTN | -14.95% | $615.01M | -17.44% | 4.80% |
| SAFT | -14.85% | $1.25B | +10.17% | 4.36% |
| FCF | -14.57% | $1.89B | +40.91% | 2.77% |
| REYN | -14.35% | $5.79B | +3.76% | 3.35% |
| SUPN | -14.04% | $1.96B | +30.48% | 0.00% |
| KMPR | -13.64% | $4.52B | +69.87% | 1.75% |
| AOMR | -13.56% | $220.30M | -5.07% | 17.13% |
| SJM | -13.50% | $11.91B | -0.25% | 3.82% |
| ASPS | -13.29% | $22.36M | -80.26% | 0.00% |
| EGBN | -13.08% | $861.65M | +20.89% | 5.30% |
ETF's related to NVO
News
SeekingAlpha
Despite attractive valuation metrics, Hershey faces challenges like stagnant earnings growth. Read why HSY stock is a compelling value investment.
Yahoo
Weight-loss drug makers are directly targeting employers in a campaign to expand health insurance coverage of their popular, but pricey, medications.
SeekingAlpha
BlackRock Event Driven Equity Fund The Fund was up over the quarter with hard catalyst, soft catalyst, and credit investments all contributing to returns.
Yahoo
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Yahoo
Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health and Human Services.
SeekingAlpha
The fund posted returns of 0.00% (Institutional shares) and 0.00% (Investor A shares, without sales charge) for the third quarter of 2024.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.